David Madigan, Northeastern University, and Demissie Alemayehu, Pfizer

Early registration is open for the 2024 Annual Symposium on Risks and Opportunities of AI in Pharmaceutical Medicine, casually called AIPM 2024, a unique and timely platform for statisticians, data scientists, regulators, and other professionals to do the following:

• Address the challenges and opportunities of AI in pharmaceutical medicine and medical research
• Foster collaboration among industry, academia, regulatory agencies, and professional associations
• Propose recommendations with policy implications for proper implementation of AI in promoting public health

The symposium, which can be attended in person or virtually, will take place June 10–11 at the Northeastern University campus in Boston with the theme Generative AI in Medical Research and Drug Development: Hype or Reality? Highlights include a panel discussion by experts in the field and a keynote address by Patrizia Cavazzoni, director of the Center for Drug Evaluation and Research at the US Food and Drug Administration.

The symposium is jointly sponsored by Pfizer, Northeastern University, and the American Statistical Association.